Jaguar Health, Inc. paid a special one time dividend of one share of Series R Convertible Preferred Stock, par value $0.0001 per share for each share of…

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on October 15, 2026, Jaguar Health, Inc. (the “Company” or “Jaguar”) paid a special one time dividend of one share of Series R Convertible Preferred Stock, par value $0.0001 per share (the “Series O Preferred Stock”) for each share

Event · Dividend
Kind
special
Frequency
one-time
Record date
October 13, 2026
Payable
October 15, 2026

Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.

Original reporting
Published Nov 3, 2026, 7:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 7:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$JAGX
Neutral
high confidence
Mentioned
$JAGX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$JAGXNeutralLow
01

Why it matters

The corporate action changes the capital structure, modestly diluting existing shareholders and may affect liquidity and price perception.

02

Market read

A micro‑cap corporate action with limited market impact, primarily relevant to current shareholders and short‑term traders.

03

What to watch

Potential tax implications for preferred shareholders and the effect on future financing capacity.

Relevance 6/10Novelty 6/10Timing: immediate today

Background

Jaguar Health announced a special dividend of Series R convertible preferred stock, which automatically converted into common stock on November 2, 2026, increasing the total common share count.

Company-level read

Ticker impact

$JAGXNeutralHigh confidence
Context

Jaguar Health filed an 8‑K reporting a special one‑time dividend and conversion of Series R preferred into common shares, creating new common shares and potential dilution.

Expected impact

likely slight dilution pressure on the stock

Evidence & confidence

The filing is a primary corporate‑action disclosure; the mechanics are clear and immediate.

Market effects

Minimal impact on the biotech sector; primarily a company‑specific capital‑structure change.

Limited to U.S. micro‑cap investors; no broader regional effect.

Low global relevance; only affects Jaguar Health shareholders.

Counterpoint

Some investors may view the conversion as a catalyst for a short‑term rally if the new shares are seen as a cleanup of preferred equity.

Key entities

  • Jaguar Health, Inc.

    Biopharmaceutical company filing the 8‑K.

Related articles

$JAGXMed

Jaguar Health Reports Third Quarter 2026 Financials

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jaguar Health Reports Third Quarter 2026 Financials Jaguar’s rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical mile

$JAGXMedAI 8/10

Jaguar Health, Inc.: Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure in Third Rare Congenital Enteropathy Disorder

Jaguar Health (JAGX) announced that its drug crofelemer has shown benefits in treating intestinal failure in pediatric patients with GUCY2C gene mutation, reducing parenteral support needs. The company plans to file for FDA approval for MVID in mid-2027. Crofelemer has also shown promise in reducing parenteral support needs in patients with MVID and SBS-IF.

$JAGXMedAI 8/10

Jaguar Health unit treats infant with rare intestinal disorder

Jaguar Health Inc. (JAGX) announced its subsidiary Napo Pharmaceuticals is treating an infant with congenital sodium diarrhea using crofelemer, reducing parenteral support needs by 15%. The company plans to file a New Drug Application for microvillus inclusion disease in mid-2027, with trial data showing significant reductions in parenteral support for pediatric patients.